# Corsera Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corsera-health

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.corserahealth.com
- Total disclosed funding: $80M
- Latest round: Series A (Jan 7, 2026)
- Investors on record: 2

## About

Based in the US, Corsera Health, Inc. delivers advanced solutions for predicting and preventing cardiovascular diseases through innovative technology and scientific research.Corsera Health, Inc. specializes in cardiovascular health solutions, founded in 2025 in Boston, US. The company raised USD 80.00 mn in Series A funding on January 7, 2026, co-led by Forbion and Population Health Partners. The founder's previous ventures are not publicly disclosed.Corsera Health specializes in innovative solutions aimed at predicting and preventing cardiovascular disease through advanced technology and scientific research. Their core offerings are built upon Nobel Prize-winning science and incorporate artificial intelligence to enhance early detection capabilities. These products serve a diverse client base, including healthcare providers, research institutions, and end users focused on cardiovascular wellness, and are deployed in North America, Europe, and parts of Asia to empower individuals to make informed health decisions.Corsera Health generates revenue through a direct-to-consumer model and partnerships with healthcare providers and research organizations. Transactions typically involve subscriptions for access to their AI-driven health monitoring services, providing users with personalized insights based on cardiovascular health data. The company also engages in collaborative agreements with healthcare institutions to integrate their technology into clinical settings, enhancing patient care and facilitating data exchange while ensuring accessibility through structured pricing plans.In January 2025, Corsera Health, Inc. raised USD 80.00 mn in Series A funding to advance Phase 1 trials of COR-1004, initiate development of COR-2003, and enhance its AI platform Klotho for cardiovascular risk prediction. The company plans to expand into additional markets in Europe and Asia by the end of 2027.

## Funding rounds

- Series A, Jan 7, 2026, $80M — Forbion, Population Health Partners

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Population Health Partners (https://capitalatlas.ai/funds/population-health-partners) — Series A